


Brilaroxazine

Chemical Properties

CAS No. :	1239729-06-6
Formula:	C ₂₂ H ₂₅ Cl ₂ N ₃ O ₃
Molecular Weight:	450.36
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Brilaroxazine (RP5063) is a potent multimodal dopamine/5-HT modulator. Brilaroxazine is a partial agonist of dopamine D ₂ , D ₃ , and D ₄ receptors, 5-HT _{1A} (K _i = 1.5 nM) and 5-HT _{2A} (K _i = 2.5 nM), and has antagonist activity 5-HT _{2B} , and 5-HT ₇ receptors with K _{is} of 0.19 nM and 2.7 nM, respectively. Brilaroxazine can be used for research about cognitive impairments in neuropsychiatric and neurological diseases.
Targets(IC50)	5-HT Receptor, Dopamine Receptor
In vivo	Brilaroxazine (10 mg/kg) had efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH, with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO ₂ , and pulmonary blood vessel structural changes[3].

Solubility Information

Solubility	DMSO: 95 mg/mL (210.94 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.33 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2204 mL	11.1022 mL	22.2045 mL
5 mM	0.4441 mL	2.2204 mL	4.4409 mL
10 mM	0.222 mL	1.1102 mL	2.2204 mL
50 mM	0.0444 mL	0.222 mL	0.4441 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Bhat L, et al. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat

Bhat L, et al. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. *Eur J Pharmacol.* 2018 May 15;827:159-166.

L. Bhat, et al. Rp5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension In Rats.

Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481